Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Accelerating Medicines Partnership in Type 2 Diabetes and Common Metabolic Diseases: Collaborating to Maximize the Value of Genetic and Genomic Data

24 Apr 2025

Abstract excerpt

In the last two decades, significant progress has been made toward understanding the genetic basis of type 2 diabetes. An important supporter of this research has been the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), most recently through the Accelerating Medicines Partnership Program for Type 2 Diabetes (AMP T2D) and Accelerating Medicines Partnership Program for Common Metabolic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Kidney Disease and Diabetes
Share to Diabetes Treatment and Management
Share to Genetic Associations and Epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40272257
DOI: 10.2337/db25-0042

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Accelerating Medicines Partnership in Type 2 Diabetes and Common Metabolic Diseases: Collaborating to Maximize the Value of Genetic and Genomic DataPMID 40272257Read ↗

Progress in genetics of type 2 diabetes and diabetic complications.Semantic proximity Read ↗

Multi-omics profiling: the way toward precision medicine in metabolic diseasesSemantic proximity Read ↗

Precision medicine in type 2 diabetesSemantic proximity Read ↗

Insights into the molecular underpinning of type 2 diabetes complicationsSemantic proximity Read ↗

Multi-omics characterization of type 2 diabetes associated genetic variationSemantic proximity Read ↗

From omics to AI —mapping the pathogenic pathways in type 2 diabetesSemantic proximity Read ↗

Personalized medicine in diabetes mellitus: current opportunities and future prospectsSemantic proximity Read ↗

Precision medicine in the management of type 2 diabetes.Semantic proximity Read ↗

A multi-omics Mendelian randomization study reveals PAM as a potential therapeutic target for type 2 diabetes.Semantic proximity Read ↗

Precision medicine in diabetes: an opportunity for clinical translation.Semantic proximity Read ↗

Integrative metabolomics and genomics reveal molecular signatures for type 2 diabetes and its cardiovascular complications.Semantic proximity Read ↗

Multi-omics regulatory networks reveal the key driver genes in the development of type 2 diabetesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.